Budesonide (Lifecycle Management)
Inflammatory Bowel Disease / Eosinophilic Esophagitis
Approved/Phase 3Active
Key Facts
Indication
Inflammatory Bowel Disease / Eosinophilic Esophagitis
Phase
Approved/Phase 3
Status
Active
Company
About Dr. Falk Pharma
Dr. Falk Pharma is a well-established, research-based private company with over 60 years of expertise in gastroenterology and hepatology. It has successfully transitioned from a development-stage entity to a commercial organization, marketing a portfolio of approved small-molecule therapies for chronic conditions like ulcerative colitis, Crohn's disease, and primary biliary cholangitis. The company leverages its deep therapeutic area knowledge and the scientific platform of the affiliated Falk Foundation to drive innovation and maintain a strong market position in specialized gastrointestinal medicine. Its long-term, family-owned structure supports a focused and patient-centric strategy.
View full company profile